文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

英夫利西单抗维持治疗期间治疗药物监测与标准治疗对免疫介导炎症性疾病疾病控制的影响:一项随机临床试验

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该随机、平行组、开放标签临床试验纳入458例接受英夫利西单抗维持治疗的免疫介导炎症性疾病成人患者,比较主动治疗药物监测(TDM)与不监测药物及抗体水平的标准治疗。结果显示,TDM组持续疾病控制无恶化的比例为73.6%,标准治疗组为55.9%,调整后差异为17.6%(95%CI 9.0%-26.2%;P < .001),支持TDM。

要点

  • 主动TDM组持续疾病控制无恶化比例为73.6%,标准治疗组为55.9%。
  • 调整后差异为17.6%(95%CI 9.0%-26.2%;P < .001),支持主动TDM。
  • TDM组不良事件报告137例(60%),标准治疗组142例(63%)。

核心结论

  • 在接受英夫利西单抗维持治疗的免疫介导炎症性疾病患者中,主动TDM在维持疾病控制无恶化方面比不进行TDM的治疗更有效。
  • 需要进一步研究比较主动TDM与被动TDM、评估对长期疾病并发症的影响,并评价该方法的成本效益。

研究设计与样本

  • 随机、平行组、开放标签临床试验,纳入458例患有类风湿关节炎、脊柱关节炎、银屑病关节炎、溃疡性结肠炎、克罗恩病或银屑病且正在接受英夫利西单抗维持治疗的成人患者,来自挪威20家医院。
  • 患者于2017年6月7日至2019年12月12日招募,最终随访于2020年12月14日进行。
  • 患者按1:1随机分配至主动TDM组(n=228)或标准治疗组(n=230);454例接受随机分配干预并纳入全分析集。

主要发现

  • 主动TDM组167例(73.6%)观察到主要结局(持续疾病控制无恶化),标准治疗组127例(55.9%)。
  • 调整后差异为17.6%(95%CI 9.0%-26.2%;P < .001),支持TDM。
  • 不良事件在TDM组报告137例(60%),标准治疗组142例(63%)。

关键数值与推荐

  • 主要结局为52周研究期间持续疾病控制无疾病恶化,疾病恶化定义为疾病特异性复合评分或患者与医生共识导致重大治疗改变(换用另一种生物制剂、加用包括糖皮质激素的免疫抑制药物或增加英夫利西单抗剂量)。
  • 主动TDM包括基于计划监测血清药物水平和抗药物抗体的剂量和间隔调整。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究比较主动TDM与被动TDM、评估对长期疾病并发症的影响,并评价该方法的成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on scheduled assessments of serum drug levels, has been proposed as an alternative to standard therapy to optimize efficacy and safety of infliximab and other biologic drugs. However, it remains unclear whether proactive TDM improves clinical outcomes during maintenance therapy. OBJECTIVE: To assess whether proactive TDM during maintenance therapy with infliximab improves treatment efficacy by preventing disease worsening compared with standard infliximab therapy without TDM. DESIGN, SETTING, AND PARTICIPANTS: Randomized, parallel-group, open-label clinical trial including 458 adults with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis undergoing maintenance therapy with infliximab in 20 Norwegian hospitals. Patients were recruited from June 7, 2017, to December 12, 2019. Final follow-up took place on December 14, 2020. INTERVENTIONS: Patients were randomized 1:1 to proactive TDM with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (TDM group; n = 228) or to standard infliximab therapy without drug and antibody level monitoring (standard therapy group; n = 230). MAIN OUTCOME AND MEASURES: The primary outcome was sustained disease control without disease worsening, defined by disease-specific composite scores or consensus about disease worsening between patient and physician leading to a major change in treatment (switching to another biologic drug, adding an immunosuppressive drug including glucocorticoids, or increasing the infliximab dose), during the 52-week study period. RESULTS: Among 458 randomized patients (mean age, 44.8 [SD, 14.3] years; 216 women [49.8%]), 454 received their randomly allocated intervention and were included in the full analysis set. The primary outcome of sustained disease control without disease worsening was observed in 167 patients (73.6%) in the TDM group and 127 patients (55.9%) in the standard therapy group. The estimated adjusted difference was 17.6% (95% CI, 9.0%-26.2%; P < .001) favoring TDM. Adverse events were reported in 137 patients (60%) and 142 patients (63%) in the TDM and standard therapy groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with immune-mediated inflammatory diseases undergoing maintenance therapy with infliximab, proactive TDM was more effective than treatment without TDM in sustaining disease control without disease worsening. Further research is needed to compare proactive TDM with reactive TDM, to assess the effects on long-term disease complications, and to evaluate the cost-effectiveness of this approach. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03074656.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Syversen SW, Jørgensen KK, Goll GL, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA. 2021. PMID: 34932077. doi:10.1001/jama.2021.21316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。